Stock DYN DYNE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Market Closed - Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
34.09 USD -1.62% Intraday chart for Dyne Therapeutics, Inc. +0.50% +156.32%
Jul. 01 Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Small Cap Comp Value Index CI
Jul. 01 Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000 Value Index CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dyne Therapeutics Insider Sold Shares Worth $1,401,902, According to a Recent SEC Filing
Dyne Therapeutics Insider Sold Shares Worth $1,334,201, According to a Recent SEC Filing
Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
Dyne Therapeutics Insider Sold Shares Worth $2,583,782, According to a Recent SEC Filing
Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing
Dyne Therapeutics Prices $325.5 Million Common Stock Offering
Dyne Therapeutics Launches $300 Million Share Offering
Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Dyne Says Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell
Dyne Therapeutics, Inc. Announces Management Changes
Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes
Dyne Therapeutics Insider Sold Shares Worth $1,398,347, According to a Recent SEC Filing
Dyne Therapeutics's Q4 Net Loss Widens; Shares Down Pre-Bell
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Dyne Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Dyne Therapeutics Insider Sold Shares Worth $2,895,519, According to a Recent SEC Filing
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DYN Stock
  4. News Dyne Therapeutics, Inc.
  5. Other languages